Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Typhoid Conjugate Vaccine - EuBiologics

Next Previous
X
Search
Drug Profile

Typhoid Conjugate Vaccine - EuBiologics

Alternative Names: EuTCV; Vi-CRM197 conjugate vaccine EuTCV; Vi-CRM197 conjugated vaccine

Latest Information Update: 18 Oct 2021

Price :

$50 *

Note:
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator EuBiologics
  • Class Bacterial vaccines; Conjugate vaccines
  • Mechanism of Action Immunostimulants
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity No

Highest Development Phases

  • Phase II/III Typhoid

Most Recent Events

  • 01 Aug 2021 EuBiologics completes a phase II/III trial for Typhoid (Prevention, In adults, In infants, In children, In adolescents) in Philippines (IM) (NCT04830371)
  • 31 Aug 2019 EuBiologics completes a phase I trial in Typhoid (In adults, Prevention) in Philippines (NCT03956524)
  • 16 Mar 2019 Phase-I clinical trials in Typhoid in Philippines (In adults, Prevention) (IM) (NCT03956524)

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:
  • Contacting your organization’s admin about adding this content to your AdisInsight subscription
  • Buying a PDF version of any individual profile
  • Request a free trial
If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top